Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 297, Issue 3, 2001, Pages 1067-1073

  Shen, Hongxie ^a,b   Chen, Zhijian J ^a   Zilfou, Jack T ^a   Hopper, Elizabeth ^a   Murphy, Maureen ^a   Tew, Kenneth D ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b Ciphergen Biomarker Discovery Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; AMINOTHIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG TARGETING; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; SCAVENGING SYSTEM; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYTOPROTECTION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBROBLASTS; HELA CELLS; HUMANS; MELANOMA; MERCAPTOETHYLAMINES; MICE; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; NUCLEAR PROTEINS; PACLITAXEL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS C-MDM2; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035005458     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Abate C, Patel L, Rauscher FJD and Curran T (1990) Redox regulation of fos and jun DNA-binding activity in vitro. Science (Wash DC) 249:1157-1161.
2. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ and George DL (1999) Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 18:5954-5958.
3. Arrigo AP (1999) Gene expression and the thiol redox state. Free Radical Biol Med 27:936-944.
4. Brockman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY and Ballard DW (1995) Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol 15:2809-2818.
5. Capizzi RL (1999) The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 26:3-21.
6. Chen ZJ, Parent L and Maniatis T (1996) Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell 84:853-862.
7. Das KC, Lewis-Molock Y and White CW (1995) Activation of NF-κB and elevation of MnSOD gene expression by thiol reducing agents in lung adenocarcinoma (A549) cells. Am J Physiol 269:L588-L602.
8. Dignam JD, Lebovitz RM and Roeder RG (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11:1475-1489.
9. Douay L, Hu C, Giarratana MC, Bouchet S, Conlon J, Capizzi RL and Gorin NC (1995) Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood 86:2849-2855.
10. Gius D, Botero A, Shah S and Curry HA (1999) Intracellular oxidation/reduction status in the regulation of transcription factors NF-κB and AP-1. Toxicol Lett 106:93-106.
11. Hainaut P and Milner J (1993) Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res 53:4469-4473.
12. Harvey DM and Levine AJ (1991) p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev 5:2375-2385.
13. Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S and Prives C (1997) Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev 11:558-570.
14. Jimenez GS, Khan SH, Stommel JM and Wahl GM (1999) p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 18:7656-7665.
15. Kamata H and Hirata H (1999) Redox regulation of cellular signalling. Cell Signalling 11:1-14.
16. Karin M and Hunter T (1995) Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Curr Biol 5:747-757.
17. Karin M and Smeal T (1992) Control of transcription factors by signal transduction pathways: the beginning of the end. Trends Biochem Sci 17:418-422.
18. Kataoka Y, Murley JS, Patel R and Grdina DJ (2000) Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines. Int J Radiat Biol 76:633-639.
19. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D and Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112.
20. Kerppola T and Curran T (1995) Transcription. Zen and the art of Fos and Jun. Nature (Lond) 373:199-200.
21. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
22. Liu T, Liu Y, He S, Zhang Z and Kligerman MM (1992) Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 69:2820-2825.
23. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J and Hay RT (1992) Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res 20:3821-3830.
24. Meek DW (1999) Mechanisms of switching on p53: a role for covalent modification? Oncogene 18:7666-7675.
25. Millar JL, McElwain TJ, Clutterbuck RD and Wist EA (1982) The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR 2721). Am J Clin Oncol 5:321-328.
26. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ and George DL (1999) Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13:2490-2501.
27. North S, El-Ghissassi F, Pluquet O, Verhaegh G and Hainaut P (2000) The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 19:1206-1214.
28. Pearson RG and Songstad J (1967) Application of the principles of hard and soft acids and bases to organic chemistry. J Am Chem Soc 89:1827-1840.
29. Rainwater R, Parks D, Anderson ME, Tegtmeyer P and Mann K (1995) Role of cysteine residues in regulation of p53 function. Mol Cell Biol 15:3892-3903.
30. Ryan KM, Ernst MK, Rice NR and Vousden KH (2000) Role of NF-κB in p53-mediated programmed cell death. Nature (Lond) 404:892-897.
31. Sen CK and Packer L (1996) Antioxidant and redox regulation of gene transcription. FASEB J 10:709-720.
32. Shen H, Kauvar L and Tew KD (1997) Importance of glutathione and associated enzymes in drug response. Oncol Res 9:295-302.
33. Shen H, Schultz MP and Tew KD (1999) Glutathione conjugate interactions with DNA-dependent protein kinase. J Pharmacol Exp Ther 290:1101-1106.
34. Shen HX, Tamai K, Satoh K, Hatayama I, Tsuchida S and Sato K (1991) Modulation of class Pi glutathione transferase activity by sulfhydryl group modification. Arch Biochem Biophys 286:178-182.
35. Sherr CJ and Weber JD (2000) The ARF/p53 pathway Curr Opin Genet Dev 10:94-99.
36. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
37. Taylor CW, Wang LM, List AF, Fernandes D, Paine-Murrieta GD, Johnson CS and Capizzi RL (1997) Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer 33:1693-1698.
38. Toledano MB and Leonard WJ (1991) Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci USA 88:4328-4332.
39. Valeriote F and Tolen S (1982) Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 42:4330-4331.
40. van der Vijgh WJ and Peters GJ (1994) Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects. Semin Oncol 21:2-7.
41. Zhang X, Lai PP and Taylor YC (1992) Differential radioprotection of cultured human diploid fibroblasts and fibrosarcoma cells by WR1065. Int J Radiat Oncol Biol Phys 24:713-719.